Copyright © 2021. Inderes Oyj. All rights reserved.
Etsi
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo ilmainen tili

Onko sinulla jo Inderes-tili?

Cantargia

Analyytikko

Foorumi

Tästä Foorumille

Sisäpiirin kaupat

Nettovaikuttavuus

Artikkeli
Yhtiöjulkaisu
Muut analyysit
Cantargia: Our Comments on the Rights Issue - Redeye
22.6.
2022

Redeye provides a comment on Cantargia’s recently announced rights issue.

Tiedotteet
Notice of extraordinary general meeting in Cantargia AB (publ)
22.6.
2022

The shareholders of Cantargia AB (publ) are invited to the extraordinary general meeting on Thursday, 21 July 2022. The extraordinary general meeting will be conducted through mandatory advance voting (postal voting) pursuant to the Act (2022:121) on temporary exceptions to facilitate the execution of general meetings in companies and other associations. Therefore, it will not be possible to attend the meeting in person or by proxy.

Tiedotteet
Cantargia AB: Cantargia resolves on a fully covered rights issue of approximately SEK 250 million
22.6.
2022

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE REFER TO "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.

Tiedotteet
Cantargia AB: Cantargia to host R&D Day on nadunolimab combinational synergy in pancreatic cancer and non-small cell lung cancer
9.6.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day on Thursday, June 16, 2022 at 09:00 AM EDT (3:00 PM CET), focusing on Cantargia's lead asset, the IL1RAP-binding antibody nadunolimab, and its combinational synergy with chemotherapy in pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC).

Muut analyysit
Cantargia: Supportive data presented at ASCO - Nordea
9.6.
2022

We attended the American Society of Clinical Oncology (ASCO) conference in Chicago on 3-7 June, at which Cantargia revealed positive interim data in several presentations.

Muut analyysit
Cantargia: Commissioned research - Nordea
7.6.
2022

Cantargia presented positive interim data at the American Society of Clinical Oncology (ASCO) 2022 the past weekend. This data was related to its lead candidate nadunolimab (CAN04) in the studies CANFOUR and CIRIFOUR.

Muut analyysit
Cantargia: Positive Results at ASCO 2022 - Redeye
30.5.
2022

Redeye has a favourable view of the topline results presented by Cantargia at ASCO 2022, which we discuss in this note.

Tiedotteet
Cantargia AB: Cantargia presents new robust data at ASCO 2022 confirming promising effects of nadunolimab in treatment of pancreatic cancer
27.5.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported extended interim results in first-line pancreatic cancer (PDAC) patients treated with nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in the phase I/IIa CANFOUR trial. The efficacy was superior to historical data for chemotherapy only. In the 73 patients evaluable, median overall survival (OS) was 12.7 months with 1-year survival of 57% and median progression-free survival (iPFS) of 7.2 months. The safety profile was acceptable and in line with the earlier data set.

Tiedotteet
Cantargia AB: Cantargia: ASCO 2022 presentation strengthens positive phase IIa interim results for nadunolimab in NSCLC
27.5.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported updated interim results for non-small cell lung cancer (NSCLC) patients treated with nadunolimab (CAN04) in combination with gemcitabine and cisplatin, showing efficacy well above historical controls. With 30 patients evaluable, overall response rate (ORR) was 53%, disease control rate 83%, median progression-free survival (PFS) 6.8 months and median overall survival (OS) 13.7 months.

Tiedotteet
Cantargia AB: Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor
27.5.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new results from the phase Ib clinical trial CIRIFOUR in 15 solid tumor patients, no longer responding to PD-(L)1 inhibitor therapy, treated with nadunolimab (CAN04) as an add-on to Keytruda® (pembrolizumab). The results are positive, with favorable safety. Disease control for at least 30 weeks was also achieved by the combination in a patient subgroup, identified by lower levels of the biomarkers CRP and IL-6 and higher levels of immune cells in the tumor tissue at baseline.

Cantargia